MEDIDATA, COGSTATE PARTNER TO TRANSFORM CLINICAL TRIALS IN NEUROLOGY

KUALA LUMPUR, Oct 30 (Bernama) -- Medidata, a clinical trial solutions provider to the life sciences industry, has partnered with neuroscience solutions leader, Cogstate to reshape clinical trials and outcomes measurement for central nervous system (CNS) diseases across neurodegenerative, psychiatric, motor, and rare neurodevelopmental disorders, among others.

Together, the companies will deliver an improved experience, supported by Medidata electronic clinical outcome assessment (eCOA) that empowers customers through faster trial starts and optimal rater experiences.

This includes a streamlined rater journey through a single mobile device app and a comprehensive suite of data quality assurance solutions for CNS assessments, according to Medidata in a statement.

bootstrap slideshow

“Through our joint efforts and drawing on Medidata’s deep expertise in eCOA, AI, and sensors, we are enabling the highest endpoint data quality standard, simplifying CNS trial setup, and running automated checks on patient assessment transcripts to minimise study team burden and mitigate the potential for errors,” said Medidata Chief Executive Officer (CEO), Anthony Costello.

Meanwhile, Cogstate CEO, Brad O’Connor said: “The strategic combination of science and technology available in the Cogstate and Medidata partnership allows us to deliver unique data quality innovations for more informed clinical trial decision-making and better patient outcomes.”

By combining Medidata’s industry-leading Medidata Platform with Cogstate’s validated digital cognitive assessments, expert rater training, and monitoring solutions, this relationship will deliver higher quality data collection with increased efficiency and accuracy.

bootstrap slideshow

By leveraging the Medidata App, a powerful mobile, site-based solution, with Medidata Rave EDC and Medidata eCOA features designed for CNS trials, raters will gain greater precision in managing their studies, initiating patient site visits, and completing intricate CNS assessments on the site tablet.

The app will also offer upgraded data capture, including enhanced controls and navigation, uniquely flexible annotation options (keyboard text, handwriting, and image capture of external notes), and embedded audio recording with smart transcription to allow for greater scoring accuracy and reducing rater burden.

Leaders from Medidata and Cogstate will present a keynote and panel session at Medidata NEXT New York, sharing additional details about the partnership as well as the latest advances in CNS clinical trial optimisation.

-- BERNAMA